One year experience on EU Medical Devices Regulation (MDR) 2017/745 for single integral drug-device combination products
By Giovanni Campana2022-06-23T10:39:00
Since 26 May 2021, Article 117 of the MDR asks for a notified body opinion (NBOp) to be included in the marketing authorisation applications (MAAs) for medicinal products that are a single integral drug-device combination…
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.